‘MindfulTMS Neurocare™’, India’s first chain of super specialized neurocare centers for treating depression has been launched today by Rangsons Healthcare, which is part of NR Group, the parent company of the popular agarbathi brand Cycle Pure Agarbathies. This will be the first of its kind center to use US FDA-approved Transcranial Magnetic Stimulation (TMS) for treating Depression, Addiction and OCD in India. Rangsons is part of NR Group, a diversified business group founded in 1948, in Mysore. NR Group is the proud owners of Cycle Pure Agarbathies, India’s leading Agarbathybrand. Rangsons, founded in 1993, is the technologies arm of NR Group. Rangsons has various businesses in Defence (RangsonsDefence Solutions), Aerospace (Rangsons Schuster Technologies), Agritech (Vyodha) and now Healthcare through MindfulTMSNeurocare.
Mr. Pavan Ranga, MD of Rangsons, along with Dr. Murali Rao, MD, FACLP, Professor and Chairman Department of Psychiatry and Behavioral Neurosciences at Loyola University Chicago, USA, and Dr. JateenUkrani, Senior Psychiatrist, New Delhi were present at the event.
Around the world, TMS has evolved has an effective non-drug based treatment option or an adjunct (add-on) treatment for depression with no side-effects. It has helped thousands of patients to overcome Depression, OCD and has shown effectiveness for addictive disorders, Parkinson’s disease, Post Stroke Depression and Depression during Pregnancy. It has also been effective for whom the antidepressants may have worked only partially. Recognizing its effectiveness, numerous health insurance companies cover TMS treatment in USA and around the world.
Transcranial Magnetic Stimulation (TMS) is a non-invasive procedure that uses magnetic fields to stimulate targeted nerve cells and improves symptoms of depression and other listed conditions mentioned above. A typical TMS session lasts for about 19 minutes and the accelerated version lasts for about 9 minutes post which, the patients can resume their normal daily activity immediately.
Mr. Pavan Ranga, MD, Rangsons and Managing Partner, NR Group, “Presently, Depression and Addiction are common ailments that plagues a large section of the population in India. I have experienced first hand the agony that families of depression patients go through. In India, there is also the challenge of a taboo associated with mental illness and lack of awareness that one may be suffering from the disease. As a result, most people suffering depression do not coming out and seek help. Our goal at mindfulTMS neurocare, is to create awareness about mental illnesses and to help patients who have or have not responded to medication. Our biggest strength is that we are global. We have access to globally tested protocols and practices to help increase the efficacy of the treatment. This treatment has helped over a million people in the US and now it is being brought to India. Our psychiatrists and psychologists are trained in global best practices and to understand the unique needs of patients and develop personalized treatment plans. Our clinicians will ensure that patients will feel at home in all our clinics.”
Dr. Murali S. Rao, Professor and Chair, Department of Psychiatry and Behavioural Neurosciences, Loyola UniversityChicago, USA, “Depression afflicts a large number of adolescents, middle-aged groups and the elderly, both men and women in India, with an estimated prevalence of 56 million in India alone, as per recently published WHO report, affecting more in women than men. A large segment of depressed individuals who are in real need of treatment, are unable to get a holistic treatment and care, either because of non-availability, low awareness, prevailing stigma or discrimination of such patients. Though psychotherapy and anti-depressants are the first line of treatments available, the response and remission rates for antidepressants remain low in about 60% of depressed population, the so called treatment resistant (TRD).
“For such patients, now there is a third option, now made available – a novel, advanced and evidence-based,effective and anon-invasive approach, directly affecting the disrupted neural circuitry in the brain, which could benefit thousands of patients who are now suffering silently”
“These circuitry based disruptions during depression and corrective changes following successful course of treatment are clearly demonstrated by advanced neuroimaging technologies” as explained by Dr Murali Rao, who has been practicing this modality of treatment since it was first approved by the FDA in USA in 2008.
A state-of-the-art facility located at heart of the city, Greater Kailash II, will offer a distinguished treatment for psychological, psychiatric, and behavioural health and well-being. The team at the Centre includes Psychiatrist and Psychotherapist who have extensive experience in neuromodulation and neurostimulation. This makes the team well aligned to deliver Neurocare’s model of sustainable, evidence-based treatments to our patients
Through MindfulTMSNeurocare, the company aims to bring more such revolutionary approaches and expertise to help many people in India who are looking for a unique and proven treatment for depression.
MindfulTMSNeurocare, an initiative by Rangsons, which is a part of NR Group, is the first chain of private super-specialized TMS Neurocare centers in India. Through TMS (Transcranial Magnetic Stimulation), the US FDA-approved treatment, the clinics offer an integrated program for psychological, psychiatric and behavioural health and well-being. The comprehensive treatment program at Mindful TMS is for individuals who are suffering from; depression, Obsessive Compulsive Disorder (OCD), anxiety disorder, and mood disorder.MindfulTMS plans to have 12 clinics in India and 22 clinics globally by 2020.